Date: 2018-06-04
Type of information: Nomination
Compound: vice-president
Company: Sarepta Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 4, 2018, Sarepta Therapeutics announced the appointment of Louise Rodino-Klapac, Ph.D. to lead its newly created gene therapy business unit as vice president, gene therapy, overseeing the development of the company’s gene therapy and gene editing programs and serving as a member of the company’s executive team.
- Until her appointment with Sarepta, Dr. Rodino-Klapac was head of the laboratory for gene therapy research for Muscular Dystrophies at Nationwide Children’s Hospital and is renowned for her work in molecular genetics and gene therapy. Her ground-breaking work has involved 11 investigational new drug applications for gene therapy, research resulting in numerous field-advancing peer-reviewed publications, and the advancement of six gene therapy programs from bench to human clinical development.
- She was an Associate Professor, Department of Pediatrics, The Ohio State University College of Medicine and Principal Investigator, Center for Gene Therapy for The Research Institute at Nationwide Children's Hospital and a faculty member of the Biomedical Sciences Graduate Program and Molecular, Cellular, and Developmental Biology Graduate Programs, The Ohio State University College of Medicine.
- Dr. Rodino-Klapac will retain her position as acting chief scientific officer of Myonexus Therapeutics. In early May 2018, Sarepta announced a collaboration with Myonexus to develop potentially transformative gene therapies to treat five distinct forms of LGMD.
- Dr. Rodino-Klapac is the recipient of numerous awards, including the Forty Under 40 Award by Columbus Business First, and the Department of Pediatrics Outstanding Junior Faculty Award for Innovation. She’s the author of numerous publications, among them papers published in The New England Journal of Medicine, Annals of Neurology, and Pediatric Neurology.
- Dr. Rodino-Klapac also served as the Ruth L. Kirschstein F32 Post-doctoral Fellow, National Institutes of Health, The Research Institute at Nationwide Children's Hospital; and was a Post-doctoral Researcher, Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital. Dr. Rodino-Klapac received her bachelor’s degree in biology from Kings College, and a Ph.D. in molecular genetics from The Ohio State University.
Financial terms:
Latest news:
Is general: Yes
